Cancer is also a bigger problem than COVID-19. Scientists continue to make important strides in cancer diagnosis and treatment. In recent years there has been a great improvement in the early diagnosis of breast cancer with blood tests. Today, however, a sad development has occurred in the field of cancer treatment.

University of SouthamptonA new study conducted in . “crown-like structures” found that it could hinder breast cancer treatment. According to the researchers, the new findings emerging as a result of this study, HER2 positive that is, it could potentially be used to develop personalized treatment for patients with excess cancer-producing cells.

Overweight breast cancer patients have a higher mortality rate

Adipose tissue in the healthy human breast and body fat is an important component. The main reason for the increased risk of developing breast cancer is: is a high body mass index† According to studies, breast cancer mortality rates are higher in overweight cancer patients than in patients with a healthy body mass index.

In patients with a high body mass index, increased body fat around the chest, macrophage called inflammatory immune cells can cause the breast to accumulate in the fatty tissue. These macrophages can then surround these fat cells to form crown-like structures. This is the chest of tumors to start and grow It creates an inflammatory environment that can lead to breast cancer. How these crown-like structures affect breast cancer progression and how they respond to treatment is still unknown.

Professors Stephen Beers, Ramsey Cutress and Dr. A research team led by Charles Birts examined samples from a group of HER2+ breast cancer patients to investigate the relationship and influence between a high body mass index and the formation of crown-like structures.

Cancer spreads faster in obese people

According to the results published in a scientific research journal, overweight or obesity Significantly more crown-like structures were seen in the adipose tissue surrounding the tumor in cancer patients. It turned out that this made the disease spread faster.

The researchers later studied the surface of macrophages in these crown-like structures. CD32B potential molecular biomarker they determined. Obesity and overweight patients with subsequent biomarkers, treatment with trastuzumabie humanized intravenously administered to treat certain types of breast and gastric cancer monoclonal antibody therapy their response was significantly lower than in people of more normal weight.

According to Stephen Beers, Professor of Immunology and Immunotherapy at the University of Southampton, this study highlighted how effective trastuzumab therapy is in patients without biomarkers. beers, “These patients may benefit from lower doses of anti-HER2 therapy that can minimize the side effects they experience. We need further studies with more patients to confirm these initial findings.he concluded.

Beers and his research team are now looking for ways to change the behavior of these crown-like structures to improve breast cancer response and treatment outcomes.